Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Sandeep S. Raj, et al. on X:
“A study led by Dr. Roni Shouval of Memorial Sloan Kettering Cancer Center introduces InflaMix, a novel AI-driven model that predicts CAR-T failure in non-Hodgkin lymphoma (NHL) patients.
How it works: InflaMix integrates 14 lab & cytokine markers to detect inflammation and organ function before CAR-T therapy.
Key Findings:
- Identified an inflammatory signature linked to higher relapse & mortality risk (HR: 2.98, P < 0.001).
- Validated in 3 independent cohorts (688 NHL patients).
- Outperformed standard prognostic markers, including tumor burden.
- Works even with limited lab data (only 6 markers needed!).
Why it matters: InflaMix could help clinicians personalize treatment and improve patient outcomes with point-of-care decision-making.”
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Authors: Sandeep S. Raj, et al.
